WeVote
Log In

Bill

Bill

HRES 803

Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

119th Congress Introduced by Robert Aderholt and 11 co-sponsors

HRES 803 urges the FDA to reassess the safety of chemical abortion drugs, impacting patients and healthcare providers by ensuring transparency and updated safety information.

Submitted in House
0
WeVote Research Nonpartisan
Bill Summary · HRES 803

Summary of HRES 803

Bill Number: HRES 803
Title: Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
Status: Submitted in House
Introduced: October 10, 2025
Classification: Resolution

Purpose and Intent

HRES 803 is a resolution introduced in the House of Representatives that calls upon the Director of the Food and Drug Administration (FDA) to reassess the safety of chemical abortion drugs. The resolution is motivated by recent independent studies that have raised concerns regarding the safety and efficacy of these medications.

Key Provisions

The resolution includes two main provisions:

  1. Reevaluation of Safety:

    • The FDA is urged to conduct a thorough reevaluation of the safety of all chemical abortion drugs. This reevaluation is prompted by findings from recent independent studies that may indicate potential risks associated with these medications.

  2. Public Safety Review:

    • The resolution calls for the FDA to publicly release a comprehensive safety review of chemical abortion drugs. This review should encompass real-world outcomes and complications associated with the use of these drugs, providing transparency and information to the public and healthcare providers.

Affected Parties

The resolution primarily impacts:

  • FDA: The agency is tasked with the responsibility of reviewing and ensuring the safety of medical products, including chemical abortion drugs.
  • Healthcare Providers: Physicians and healthcare professionals who prescribe these medications may need to consider new safety information and guidelines.
  • Patients: Individuals seeking chemical abortions may be affected by changes in the availability or recommendations regarding these drugs based on the FDA's findings.

Procedural Aspects

  • Submission Date: The resolution was submitted to the House on October 10, 2025.
  • Committee Referral: It has been referred to the House Committee on Energy and Commerce for further consideration.

Conclusion

HRES 803 seeks to address concerns regarding the safety of chemical abortion drugs by urging the FDA to conduct a reevaluation and to provide a public safety review. The outcome of this resolution could have significant implications for regulatory practices, healthcare providers, and patients involved in reproductive health decisions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.